Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Bar Coding Final Rule Sets Two-Year Implementation Timeline For Existing Products

This article was originally published in The Pink Sheet Daily

Executive Summary

New products approved after April 26 would have to include bar codes on packages within 60 days. The proposed rule would have created a blanket three-year implementation period.

FDA's bar code final rule has a shorter implementation timeline than the proposed rule.

Under the 1 final rule, "Bar Code Label Requirements For Human Drug Products and Biological Products," manufacturers have two years to apply the bar code requirements to products approved before April 26, the rule's effective date.

For new drugs approved on or after April 26, the bar code must be added within 60 days of approval.

The proposed rule would have created a three-year implementation period for all products.

The rule requires bar codes on the packages of most prescription drugs and biologics, and over-the-counter drugs commonly used in hospitals. It is expected to be published in the Federal Register on Feb. 26.

FDA estimates that once fully implemented, the bar code rule will save $93 bil. over 20 years and prevent almost 500,000 adverse events.

At a Feb. 25 press conference in Washington, FDA Commissioner McClellan called these estimates "conservative," noting that in some bar coding studies, medication errors were reduced by up to 85%.

- Elizabeth Walker

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel